BIOLARGO, INC. 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   The following is a report of the sales of unregistered securities during the period covered by this report not previously reported in an annual report on Form 10-K, a Quarterly Report on Form 10-Q, or a Current Report on Form 8-K.   During the three months ended June 30, 2021, pursuant to an offering commenced in May 2020 (the “2020 Unit Offering”), we sold 2,556,547 shares of our common stock and received $400,000 in gross and net proceeds from four accredited investors. In addition to the shares, we issued the investors six-month and a five-year warrants to purchase an aggregate 5,113,094 additional shares.   On June 30, 2021, we issued 172,059 shares of our common stock, and options to purchase 17,647 shares of our common stock, at $0.17 per share in lieu of $31,000 of accrued and unpaid obligations to consultants.   All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4(2) of the Securities Exchange Act and/or Regulation D promulgated thereunder as not involving a public offering of securities.   37 Table of Contents